PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

PHARMApharmadossier

Topic

Breakthrough Therapy

FDA breakthrough therapy designation, expedited development, evidence expectations, and launch-planning implications.

2 articles·Lives underPipeline Approvals·Last updated 2026-06-11

Approvals· June 11, 2026 · 10 min read

FDA Commissioner's National Priority Voucher program: what launch teams need to know

By Ran Chen#FDA Approval #Accelerated Approval #Priority Review

Pipeline· June 5, 2026 · 12 min read

Gedatolisib PDUFA preview: pan-PI3K/mTOR inhibitor targets HR+/HER2– breast cancer gap

By Ran Chen#PDUFA Date #FDA Approval #Clinical Evidence